Many cytokines and growth factors trigger rapid changes in gene expression upon binding to their receptors. In many cases, the mechanism by which these changes are affected is unknown. In this report, we show that interleukin-2 (IL-2). IL-3, IL-4,11-6, leukemia inhibitory factor (LIF), erythropoietin (Epo), and granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of cells causes rapid activation of DNA-binding activities that recognize a DNA sequence element previously implicated in regulation of gene expression by interferon y (IFNy). The IL-4-, IL-6-, and GM-CSF-induced complexes can be distinguished from the recently YTOKINES and growth factors comprise a large and diverse family of soluble polypeptides that control the growth, differentiation, and function of mammalian cells. These effects are mediated via binding to specific cell surface receptors that in some way transduce signals that ultimately elicit a phenotypic response.'-4 Abundant evidence shows that changes in the transcription rate of specific genes are an important component of this response. This is thought to be a consequence of alterations in the amount or activity of specific DNA-binding proteins. In some instances, considerable progress has been made in defining the pathway that leads from a receptor-ligand interaction at the cell surface to changes in the activity of such nuclear factors." However, it is also becoming apparent that many growth factors trigger the same second messenger systems, which raises the question of how ligand-specific responses are e l i~i t e d
YTOKINES and growth factors comprise a large and diverse family of soluble polypeptides that control the growth, differentiation, and function of mammalian cells. These effects are mediated via binding to specific cell surface receptors that in some way transduce signals that ultimately elicit a phenotypic response.'-4 Abundant evidence shows that changes in the transcription rate of specific genes are an important component of this response. This is thought to be a consequence of alterations in the amount or activity of specific DNA-binding proteins. In some instances, considerable progress has been made in defining the pathway that leads from a receptor-ligand interaction at the cell surface to changes in the activity of such nuclear factors." However, it is also becoming apparent that many growth factors trigger the same second messenger systems, which raises the question of how ligand-specific responses are e l i~i t e d .~.~ Despite these advances, the signal transduction pathways used by many growth factors and cytokines to alter gene expression remain unclear. Many cytokine and growth factor receptors, such as those for interferons (IFNs), tumor necrosis factor (TNF), interleukins (ILs), granulocyte-macrophage colony stimulating factor (GM-CSF), and erythropoietin (Epo) do not have recognizable intracellular kinase dom a i n~. ' -~.~ Although known second messengers have been implicated in signal transduction in response to some of these factors, their role in modulating gene expression remains speculative. ',6 Progress in resolving these issues has been made recently in the I F N system. IFNs a and p (type I) act as a primary nonspecific defense against viral infections.' IFNy (type 11) has antiviral properties but also plays a major role in regulation of the immune response.8 Type I and type I1 IFNs bind to distinct cell surface receptors and cause rapid alterations in gene e x p r e~s i o n .~~~~~ Specific sequence elements have been identified in the promoters of genes that respond to IFNa and IFNy. IFN-stimulated response elements (ISREs) are both necessary and sufficient for regulation by IFNcz.~ An ISRE binding protein complex, ISGF3, is rapidly induced upon treatment of cells with IFNa."." Recently, cDNAs encoding the proteins that constitute ISGF3 have been isolated and chara~terized.""~ ISGF3 is a complex of four proteins, called p48, p84, p91, and p1 13. p48 is the DNA- binding component of ISGF3 and has homology to myb.14 p84 and p91 are probably alternatively spliced products of the same gene and are related to ~113.''.'~ p84, p91, and p1 13 are novel proteins that contain SH2 and SH3 domains and are found in the cytoplasm of untreated ce1ls.l5 IFNa treatment of cells results in rapid tyrosine phosphorylation of p84, p91, and p1 13, causing them to associate and form a heteromeric complex with p48 to form ISGF3, which then translocates to the nucleus and binds to ISREs, thus stimulating trans~ription.'~.'~.'~ Regulation in response to IFNy is conferred by a distinct sequence, ie, the gamma-activated sequence (GAS).I7-l9 Treatment of cells with F N y results in tyrosine phosphorylation of p9 l alone, which then translocates to the nucleus in an uncomplexed form and binds to the GAS."." Thus, the specificity of binding of either IFNa or IFNy to its receptor is translated into a specific phosphorylation pattern within a related family of latent transcription factors. This pattern of phosphorylation dictates the association state of the proteins, which determines specificity of binding to either an ISRE or a GAS and the subsequent transcriptional response.
IFNa and IFNy are unrelated to each other at the primary sequence level and bind to distinct receptor^.^.^.' However, treatment of cells with either IFN results in tyrosine phosphorylation of a common substrate, p9 1. Because tyrosine phosphorylation of proteins is a common response to the interaction of cytokines or growth factors with their receptors,l.4.21-24
we investigated whether p9 1 phosphorylation might occur in response to cytokines or growth factors other than IFNs. Because tyrosine phosphorylation of p91 allows it to bind to a GAS, we assayed for p91 activation by monitoring the appearance, in cell extracts, of DNA-binding proteins capable of interacting with a GAS in response to various cytokines and growth factors. We find that novel GAS-binding complexes are rapidly induced by several cytokines. These complexes can be differentiated from activated p91 produced by IFNy treatment on the basis of size, sequence preference, and reactivity with an anti-p91 antiserum.
Evidence is presented that proteins required for the formation of these new protein-DNA complexes are phosphorylated on tyrosine.
MATERIALS AND METHODS
Reagents. Oligonucleotides were obtained from National Biosciences (Plymouth, MN). IFNCY, IFNy, and anti-p91 sera were the gift of Dr J. Damell (Rockefeller University, New York, NY). Recombinant TNFol, IL-la, and IL-6 were obtained from R&D Systems (Minneapolis, MN). E-2, IL-4, GM-CSF, and leukemia inhibitory factor (LIF) were obtained from Genzyme (Boston, MA) or GIBCO-BRL (Gaithersburg, MD). The source of IL-3 was WEHI-3B conditioned medium supplemented with 50 ymol/L 2-mercaptoethanol, and of IL-2 was plasmacytoma conditioned medium supplemented with 50 pmol/L 2mercaptoethanol. Recombinant human Epo was the kind gift of Ross Basch (New York University School of Medicine, New York, NY). The antiphosphotyrosine monoclonal antibodies used were 4G10 (Upstate Biotechnology Inc, Lake Placid, NY), PY20 and PY69 (Transduction Labs, Lexington, KY), and AB-l (Oncogene Science, Uniondale, NY). Protein A agarose, calf intestinal alkaline phosphatase, protease inhibitors, and poly d(1-C) poly d(1-C) were from Boehringer Mannheim (Indianapolis, IN).
Cells and cell culture. HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mmol/L glutamine, and 100 U/mL of penicillin and streptomycin. U937 cells were obtained from Dr J. Darnel1 and grown in RPM supplemented with 10% FBS, 2 mmoVL glutamine, and 100 U/mL of penicillin and streptomycin. HepG2 cells were treated with cytokines at 50% to 75% confluency and U937 cells were treated at a density of 2 X lo5 to 5 X lo5 cells/mL. BaF3/ ER, LyD9, and CTLL cells were starved of the appropriate cytokine for 4 hours before treatment with fresh media containing cytokine for 15 minutes. Cytokines were used at the following concentrations: IFN-y, 5 ng/mL; IFNa, 1, OOO U/mL; TNFcY, 50 ng/mL; IL-ICY, 50 ng/mL; IL-2, 50 ng/mL (U937) or 150 U/mL (CTLL); IL-3, 150 U/ m L ; IL-4. 20 ng/mL; IL-6, 50 ng/mL; GM-CSF, 10 ng/mL; Epo, 150 U/mL; and LIF, 50 ng/mL. Preparation of nuclear extracts and gel retardation assays. Nuclear extracts were prepared by NP40 lysis as described by Sadowski and Gilmam' Protein concentrations were measured using the Bradford dye binding assay. The GAS oligonucleotide is based on an IFNy-responsive element in the Ly6E gene promoter,'* and was formed by annealing oligonucleotides with the sequences GATCCA-CTTACAGGAATAT and GATCATATTCCTGTAAGTG. Oligonucleotide competition was performed by preincubating nuclear extract with the competitor oligonucleotide and poly d(1-C) poly d(I-C) for 10 minutes at room temperature before the addition of labeled probe. Phosphatase treatment of extracts was performed by diluting extract into 13 mmoVL HEPES (pH 7.9), 1 rnmoVL DTT, 8% glycerol, and then incubating in the presence of calf intestinal alkaline phosphatase for 15 minutes at room temperature. Poly d(I-C) poly d(1-C) and labeled probe were then added, and the incubation continued for 20 minutes before resolving complexes on polyacrylamide gels.
Immunodepletion and immunoblotting. For depletion with antisera, 30 Mg of nuclear protein was diluted to 20 pL with 13 mmoV L HEPES (pH 7.9), 0.1 moVL potassium chloride, 1 mmol/L DTT, and 8% glycerol. One microliter of the appropriate antiserum was added and the mixture further diluted to 100 pL with the above buffer lacking potassium chloride. The extract was then incubated with the antisera for 1 hour at 4°C on a rotating wheel. Twenty microliters of a 50% slurry of protein A agarose was then added and the incubation was continued for another 30 minutes. The mixture was finally centrifuged at 3,500 rpm for 10 minutes at 4°C and the supernatant (depleted extract) was used directly in gel retardation assays without further dilution. Extracts to be analyzed by Western immunoblotting were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 8% Tris-glycine gels (Novex, San Diego, CA). Proteins were then transferred to nitrocellulose, and the filter was blocked in 5% nonfat milk proteins in Tris-buffered saline (20 mmoV L Tris, 137 mmol/L sodium chloride [pH 7.61) containing 0.1% Tween 20 (TBS-T) for between 1 and 16 hours. Filters were then incubated with primary antibody diluted 1:4,000 in TBS-T for 1 hour. After extensive washing, bound antibody was detected using enhanced chemiluminescence reagents (Amersham, Arlington Heights, IL) according to the manufacturer's instructions.
Transient transfection assays. The reporter plasmids GAS-TK luc and ISRE-TK luc contain either GAS or ISRE sequences linked to the promoter of the Herpes Simplex virus thymidine kinase gene at position -35 with respect to the cap site. These chimeric IFNresponsive promoters drive the expression the structural gene for firefly luciferase. The sequence of the GAS is the same as the one used in the gel retardation analyses. The sequence of the ISRE is CTCGGGAAAGGGAAACCGAAACTGAAGCC. These constructs were the kind gift of Dr J. Damell. HepG2 cells were transfected by calcium phosphate coprecipitation. Cells were seeded at 2 X 10' cells/mL the day before transfection. Cells were exposed to a calcium phosphate precipitate containing 15 &nL GAS-TK luc reporter or ISRE-TK luc reporter and 5 pdmL of the P-galactosidase-expressing plasmid pCHllO for 5 hours. The medium was then changed and the cells were allowed to recover for 16 hours. Recombinant cytokines were then added directly to the medium and the cells harvested 5 hours later. Cells were lysed and luciferase and pgalactosidase activities determined using standard techniques. For each sample the normalized response was determined by dividing relative light units obtained from the luciferase assay with the Pgalactosidase activity in the same lysate as determined using a chromogenic substrate. Each point in Fig 5 represents the average normalized response from three experiments.
RESULTS

Rapid induction of DNA-binding proteins by cytokines.
Treatment of human fibroblast cell lines with IFNy results
in the rapid induction of a DNA-binding activity termed the gamma-activated factor (GAF) that can be detected by gel retardation using a GAS We examined this induction in the human hepatoma cell line HepG2. Treatment of HepG2 cells with IFNy for 15 minutes results in the appearance in cell extracts of a protein that binds to the GAS that is not present in extracts of untreated cells (Fig la) . The amount of this complex is diminished after 1 hour of treatment. These kinetics are similar to those previously observed in fibroblasts.m*26 The complex detected in HepG2 cells is almost certainly identical with that seen in fibroblasts and contains p91 (see below). Treatment of HepG2 cells with IFNa also results in the induction of a GAS binding activity within 15 minutes (Fig la) but at significantly lower levels. This complex comigrates with the IFNy-induced complex, and is abolished by incubation of the extract with a p91 antiserum (data not shown). The IFN-induced complex is specifically competed by an excess of unlabeled GAS oligonucleotide, but not by an excess of the unrelated ISRE oligonucleotide, demonstrating its sequence specificity (Fig la) .
To determine whether any other cytokines were capable of inducing GAS-binding activity, nuclear extracts from HepG2 cells treated with either IL-6, LIF, IL-la, or TNFa, were incubated with radiolabeled GAS DNA. Free and complexed DNA were then resolved by nondenaturing gel electrophoresis. IL-6 induces the formation of two complexes, A and B, within 15 minutes (Fig lb) . Complex A, the less abundant of the two, comigrates with the complex formed by extracts from IFNy-treated cells. Complex B migrates more slowly in the gel. Both complexes are barely detectable in extracts from cells treated for 1 hour. LIF, which shares many biologic similarities with L-6, induces a single complex. This complex comigrates with complex B induced by IL-6. However, the kinetics of its appearance are different. The LIFinduced complex is detectable after 15 minutes of treatment and reaches a peak after 30 minutes, but by 60 minutes has decayed. The IL-6-induced complexes are maximally induced by 15 minutes and then decay. Neither L -l a or TNFa induces the appearance of proteins capable of binding to the GAS at any of the time points examined. HepG2 cells are known to have receptors for these cytokines and have been used previously in studies of gene regulation by IL-l and TNF. 27.28 HepG2 cells lack receptors for many growth factors and cytokines. To test whether other cytokines could induce proteins capable of binding to the GAS, nuclear extracts were prepared from the U937, BaF3/ER, LyD9, and CTLL cell lines. U937 is a human promonocytic cell line, BaF3/ER is a murine IL-3-dependent B-lymphoid progenitor line stably transfected with the Epo receptor, LyD9 is a murine IL-3-dependent B-lymphoid progenitor line, and CTLL is a murine IL-2-dependent T-cell line. Extracts prepared from U937 cells treated with either GM-CSF, IL-2, or L -4 were assayed by gel retardation using radiolabeled GAS DNA. The results are shown in Fig IC. GM-CSF induces the appearance of a single major complex not present in extracts of untreated cells. This complex is present after 15 minutes of treatment, becomes more abundant after 30 minutes, and is still present at high levels after 1 hour of treatment. The complex migrates at a position between the complexes induced by IFNy and IL-6 in HepG2 cells (Fig IC) . IL-2 induces a single complex of low abundance in U937 extracts at all time points studied. JL-4 induces two new complexes, apparent after 15 minutes of treatment and increasing in abundance up to 1 hour. Extracts prepared from BaF3/ER or LyD9 cells treated with IL-3 for 15 minutes give a single induced complex (Fig Id) . A 15-minute treatment with Epo also induces a single complex in extracts of BaF3ER cells that migrates close to the IL-3-induced complex. Finally, IL-2 strongly induces a single complex in extracts of CTLL cells, which has a similar mobility to the complexes induced by IL-3 and Epo.
These experiments demonstrate that IL-2, IL-3, IL-4, IL-6, LIF, Epo, and GM-CSF, in addition to IFNy and IFNa, can induce the rapid appearance of factors capable of binding to the GAS in a gel retardation assay. The inability of TNFa or IL-la to induce GAS-binding complexes in similar experiments indicates that induction of such complexes is not a property cormnon to all cytokines.
Sequence specijicity of cytokine-induced complexes. The sequence specificity of the complexes induced by IFNy, IL-4, IL-6, and GM-CSF was tested by comparing the ability of 12 oligonucleotides, each containing a single point mutation with respect to the GAS, to compete for binding of the complexes to the wild-type GAS. Nuclear extracts from cells treated with IFNy for 15 minutes or from cells treated for 30 minutes with either IL-4, IL-6, or GM-CSF were incubated with several concentrations of unlabeled competitor oligonucleotide for 10 minutes before the addition of radiolabeled wild-type GAS. Complex formation was then assessed by gel retardation. The ability of the different oligonucleotides to compete for binding of the induced complexes is summarized in Fig 2a. Competition of the cytokine-induced complexes is seen with some oligonucleotides but not with others, demonstrating their sequence specificity. Most of the oligonucleotides have a similar profile with respect to their ability to compete for the various cytokine-induced complexes. However, one oligonucleotide, 8T, competes effectively for the complex induced by IFNy but not for the complexes specific for IL-4, IL-6, or GM-CSF (Fig 2b) . The IL-6-induced complex A that migrates in the same position as the complex induced by IFNy is also competed by this oligonucleotide, whereas complex B is not. This demonstrates that the sequence preference of the IFNy-induced complex differs from those of the complexes induced by other cytokines.
Involvement of p91 in cytokine-induced complexes. The ability of IL-4, IL-6, and GM-CSF to induce activities capable of binding to a GAS, a known binding site for the IFNyactivated protein p91, led us to test for the presence of p91 in these complexes. Extracts from untreated cells or from cells treated with IFNy, IL-4, IL-6, or GM-CSF were incubated with anti-p91 antiserum or control serum, The antiserum was then cleared from the extracts, and the resulting supernatants, which are depleted of all the p91 accessible to the antiserum, were then used in both gel retardation and Western blot assays. Depletion of extracts with anti-p91, but not nonimmune, antiserum removes the IFNy-induced -v " --complex quantitatively (Fig 3a) . In extracts from IL-6-treated cells, complex A is completely removed by depletion with anti-p91 antiserum, whereas complex B is unaffected. Likewise, the complexes formed by extracts from cells treated with IL-4 or GM-CSF are unaffected by depletion with either antiserum. A slowly migrating nonspecific band is present in all samples that have been treated with antiserum. Figure 3b shows a Western blot of the same extracts used in the gel retardation probed with the anti-p91 antiserum. In each case, treatment with nonimmune serum has little effect on p91 levels, whereas treatment with the antip91 antiserum removes all the detectable p91 in the extract. Therefore, if p91 is a component of the IL-4, IL-6B, or GM-CSF complexes, it is present at levels below the limits of detection of this Western blot experiment.
Extracts have also been depleted using antisera to two other proteins known to be involved in IFN signal transduction, p1 13 and p48. Depletion of either of these proteins has no effect on the GAS binding complexes induced by IFNy, IL-4, IL-6, or GM-CSF (data not shown).
Evidence that proteins involved in cytokine-induced GASbinding complexes are phosphorylated on tyrosine. The fact that p91 is rapidly phosphorylated on tyrosine in response to IFNY,~" and the observation that many cytokines, including IL-4, IL-6, and GM-CSF, cause rapid tyrosine phosphorylation of proteins upon binding to their reception of the novel cytokine-induced complexes might contain phosphotyrosine. To investigate this possibility, we used a similar strategy to that described above. Extracts from untreated and treated cells were depleted of phosphotyrosinecontaining proteins using a cocktail of antiphosphotyrosine antibodies, and then tested in the gel retardation assay. The results are shown in Fig 3a. Depletion of extracts from IFNytreated cells with the antiphosphotyrosine antibody cocktail results in a marked diminution of the induced complex. The A complex induced in extracts from IL-6-treated cells shows similar behavior. However, the B complex is unaffected by depletion of the extract with the antiphosphotyrosine antibody cocktail. In contrast, complexes induced by IL-4 and GM-CSF are completely abolished by depletion with the antiphosphotyrosine antibodies. These results clearly implicate phosphotyrosine-containing proteins as necessary for the formation of the IL-4, ILdA, GM-CSF, and IFNy complexes. The fact that the IL-6-induced comtors,l.21-24 suggested that the proteins involved in the forma-2067 plex B is unaffected by the antiphosphotyrosine antibody depletion could either reflect a lack of phosphotyrosine-containing proteins in this complex or the inability of these particular antibodies to bind phosphotyrosine in the context of this complex.
We then examined the effect of phosphatase treatment on the different extracts. Extracts were incubated with increasing amounts of calf intestinal alkaline phosphatase before being used in the gel retardation assay. The results are shown in Fig 4. Phosphatase treatment diminishes the abundance of the IFNy-induced complex in a dose-dependent fashion. This is in agreement with previous data showing that p91 phosphorylation is required for GAS binding." As expected, the IL-6-induced complex A is also sensitive to phosphatase treatment. Complex B appears to be more sensitive, as evidenced by the change in the ratio of complex A to complex B with increasing phosphatase concentration. The GM-CSFand IL-4-induced complexes are also abolished by phosphatase treatment. Phosphorylation of proteins in these complexes is therefore required for GAS-binding activity.
GAS-dependent transcriptional activation by cytokines. The GAS confers transcriptional inducibility by IFNy on a minimal promoter in transient transfection assays.26 We tested whether the GAS could mediate transcriptional induction in response to other cytokines using a construct that consists of a GAS linked to minimal promoter and the structural gene for firefly luciferase. This plasmid, together with a plasmid that expresses &galactosidase, was transfected into HepG2 cells by calcium phosphate coprecipitation. Sixteen hours later, cells were treated with increasing doses of IFNy, IFNa, IL-6, or LIF for 5 hours and then harvested and lysed. The lysates were assayed for luciferase and pgalactosidase activity. The luciferase activities normalized with respect to @-galactosidase (as described in Materials and Methods) are shown in Fig 5a. IFNy gives a 40-fold induction of luciferase activity (determined by dividing the normalized response in the presence of IFNy by the normalized response in its absence) at a concentration of 5 ng/mL, with demonstrable activity at 0.3 ng/mL. The response to IL-6 is almost identical. In contrast, LIF and IFNa show a maximal induction of fivefold over background. To test the dependence of these transcriptional effects on the GAS, an IFNa-specific ISRE was used to replace GAS in the reporter construct described above. This new construct was transfected into HepG2 cells and tested for induction by the 9c   TA'TTCCTGTAAGTG  TG'TKCTGTAAGTG  'ITITCC'TGTAAGTG  TC'TKCTGTAAGTG  TA?TDCIY;TAAGTG  TA'ITTCTGTAAGTG  TA'TTCCGGTAAGIY;  TA'TTCCAGTAAGTG  T A " T A A G T G  TA'TTCCTGGAAGTG  TA'TTCCTGAAAGTG  TA'TTCCTGCAAGTG   +++ +++ +++   ------+++ +++ same cytokines. As expected, IFNa induces this construct, giving a fivefold increase in luciferase activity (Fig 5b) . However, neither IFNy, IL-6, nor LIF induce this construct at any concentration tested. These results show that IL-6 and LIF can activate transcription from a GAS element, implying a role for the induced GAS-binding complexes in the regulation of gene expression. In contrast, TNFa and IL-la are LAMB ET AL unable to induce luciferase expression from the GAS reporter in HepG2 cells (data not shown), which is consistent with their inability to induce GAS-binding complexes in the gel retardation assay.
DISCUSSION
We examined the activation of GAS-binding proteins in response to IFNy and IFNa in HepG2 cells. In agreement with previous findings in other cell line^,'^,'^." we find that IFNy treatment of HepG2 cells results in rapid activation of a tyrosine-phosphorylated GAS-binding protein that reacts with an anti-p91 antiserum. We also find that IFNa treatment of HepG2 cells yields a low amount of a GAS-binding complex with the same mobility as that induced by IFNy. This complex contains p91 on the basis of its reactivity with an anti-p91 antiserum. These data show that small amounts of uncomplexed activated p91 are produced in HepG2 cells in response to IFNa. The induction of a GAS-binding activity in response to IFNa has been reported previously in other cells,18.26 although the magnitude of the induction appears to be cell line dependent. An attractive explanation for these results is that the stoichiometry of p91 to p1 13 varies in different cell lines, resulting in varying amounts of complexed and free p91 being produced in response to IFNa in different cell types. This suggests that in cells where p91 is in excess with respect to p1 13, IFNa treatment will result in activation of both IFNa-and IFNy-responsive genes. Conversely, in cells where p1 13 is in excess with respect to p91, IFNa treatment will result in activation of IFNaresponsive genes only.
IFNa and IFNy have no amino acid sequence homology to one another and bind to unrelated cell surface Their common ability to activate p91 prompted us to look for activation of p91 in response to other cytokines using a gel retardation assay. TNFa and IL-la failed to induce any GAS-binding proteins. In contrast, IL-2, IL-3, L-4, IL-6, LIF, Epo, and GM-CSF all induced GAS-binding proteins within 15 minutes of stimulation. The speed with which these complexes are induced suggests that they are composed of pre-existing as opposed to newly synthesized proteins, although we have not tested this conjecture directly. To our surprise, only L -6 induced a complex that comigrated with the IFNy-induced p91 complex. This complex is indistinguishable from the IFNy-induced complex by all criteria tested, including reactivity with an anti-p91 antiserum. We therefore conclude that IL-6 is capable of activating p91 in HepG2 cells.
The other cytokine-induced complexes have mobilities distinct from that characteristic of activated p91. The mobilities of the LIF-and IL-6-induced complexes are indistinguishable, although the kinetics of their appearance differ. It is interesting that, in contrast to L-6, LIF does not induce p91. The receptors for LIF and L -6 share a common subunit, gp130, that is necessary for signal transduction after interaction of these cytokines with their respective receptors.' LIF and IL-6 share many bioactivities, although they also have distinctive proper tie^.^.^^ Our results show that the association of either the LIF-or IL-6-binding subunit of the receptor with gp130 induces distinct patterns of GAS-binding proteins in HepG2 cells, which could ultimately lead to distinct patterns of gene activation. This hypothesis is consistent with the transient transfection data presented in this report. Although both LIF and IL-6 activate transcription via a GAS element, IL-6 does so to a much greater extent.
Upon binding to their receptors, many cytokines and growth factors, including IL-4,23 GM-CSF,2'.24 and IL-6,"22 induce rapid tyrosine phosphorylation of proteins. We find that phosphotyrosine proteins are components of the IL-4-, ILdA-, and GM-CSF-induced complexes. Binding of all complexes to the GAS was inhibited by phosphatase treatment, suggesting that phosphorylation is required for DNAbinding activity. These data suggest that latent GAS-binding proteins are one of the substrates of tyrosine kinases activated in response to cytokine treatment, and that phosphorylation activates DNA binding. Several recent reports have described the rapid induction of DNA-binding proteins in response to growth factors or and IL-6 have been ~tudied.~~.~~.'"" We note that the DNA sequences used as gel retardation probes in these experiments are related to the GAS sequence used by us. The IL-6-induced complexes described appear to be analogous to those observed by us.
GM-CSF-induced DNA-binding complexes have also been reported and partially characteri~e d . '~ The probe used in these studies was a relatively long (39 bp) fragment from the Fcy receptor gene promoter. The exact sequence that these complexes binds to and their relationship to the complex described in this report are unclear.
The results presented here and described elsewhere demonstrate the ability of many cytokines and growth factors to induce DNA-binding complexes that interact with the GAS cytokines.2S.2V'34 In particular, complexes induced by EGF and related elements. Our data suggest a lack of involvement of the I F N y and IFNa-activated proteins p91, pl13, and p48 in many of these complexes. p91 and p1 13 are homologous to one another but not to any other transcription factors. As such, they constitute a new family of proteins that play a key role in activation of transcription in response to IFNs. It is likely that p91 and p113 are members of a larger superfamily of latent transcription factors. By analogy with the intracellular receptor superfamily, whose members are involved in regulation of transcription in response to small molecules, other members of this new superfamily are likely to play a role in modulation of gene expression in response to cytokines and growth factors other than the IFNs. Preliminary data suggest that additional members of the p91 and p113 family exist."
The signal transduction pathway recently described for the IFNs may be prototypic of a family of such pathways that are activated in response to a variety of cytokines and growth factors: The data presented here are consistent with this proposal and allow us to suggest a similar model for the signaling pathways involved in modulation of gene expression in response to IL-4, IL-6, LIF, and GM-CSF. In this model, unstimulated cells contain latent transcription factors in the cytoplasm. In response to the binding of a particular cytokine to its receptor, a tyrosine kinase is activated that phosphorylates one or more of these proteins. This phosphorylation results in translocation to the nucleus and in some cases association with other proteins that impart the relevant DNA binding specificity. Upon binding to specific response elements, these complexes then modulate the transcription of cytokine-responsive genes, ultimately resulting in changes in cell phenotype. Thus, the rapid activation of specific sets of latent transcription factors ultimately mediates long-term changes in cell phenotype that are characteristic of a particular cytokine or growth factor. In contrast, short-term responses may be mediated via parallel signal transduction 
